S-1/A: Aspire Biopharma Registers Shares Amidst Financial Strain

Aspire Biopharma Holdings, Inc. files S-1/A to register up to 147 million shares for resale, reporting significant losses and going concern doubt despite positive aspirin clinical trial results.

Summary

• Aspire Biopharma Holdings, Inc. (formerly PowerUp Acquisition Corp.) completed a business combination on February 17, 2025, becoming a Delaware corporation focused on novel sublingual drug delivery.
• The company is registering up to 147,177,424 shares of common stock for resale by selling shareholders, convertible from promissory notes with an aggregate principal of $9,687,500 and a subscription price of $7,750,000.
• Of the $7,750,000 funding, $4,709,677 was received on August 19, 2025, $1,000,000 on September 22, 2025, and the remaining $2,250,000 is contingent upon the registration statement's effectiveness.
• A recent in vivo single-dose bioavailability study for high-dose sublingual aspirin concluded in July 2025, with the final report received on September 5, 2025, showing faster bloodstream entry and more significant platelet inhibition (TXB2) compared to standard oral aspirin.
• The company plans to submit a section 505(b)(2) New Drug Application (NDA) for its high-dose aspirin product in Q3 2025 and seek fast-track approval.
• Aspire has developed sublingual formulations for melatonin, vitamins D, E, K, testosterone, and is in final phases for semaglutide, with caffeine products (Buzz Bomb Caffeine Co. LC) launched online in August 2025.
• The company reported a net loss of $17,922,621 for the six months ended June 30, 2025, and an accumulated deficit of $20,699,854.
• As of June 30, 2025, the working capital deficit was $9,567,500, and cash was $206,233, raising substantial doubt about the company's ability to continue as a going concern.
• Nasdaq issued notices on April 16, 2025, regarding non-compliance with the minimum Market Value of Listed Securities ($50M) and minimum bid price ($1.00) requirements, with a compliance period ending October 13, 2025.
• The company incurred $14,131,250 in stock-based compensation expense in February 2025 related to shares issued to an advisory firm for business combination services.
• Kraig Higginson was appointed Interim Chief Executive Officer on July 24, 2025, following Michael Howe's resignation.
• The company's intellectual property includes pending patent applications for sublingual aspirin formulations (expiring March 29, 2044, and October 1, 2045) and new trademark applications for 'Instaprin', 'Buzz Bomb', 'Coffee Shot', and 'CaffeineAccelerated'.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including significant losses, a working capital deficit, and substantial doubt about its ability to continue as a going concern. Nasdaq delisting notices add immediate pressure. While product development, particularly for sublingual aspirin, shows promise, the overwhelming financial and operational challenges overshadow these positives, indicating a high-risk investment.

Positives

• Successfully completed a clinical trial for high-dose sublingual aspirin, demonstrating faster bloodstream entry and more significant platelet inhibition (TXB2) than conventional oral aspirin, with no adverse reactions.
• Plans to submit a section 505(b)(2) NDA for high-dose aspirin in Q3 2025 and seek fast-track approval, leveraging over 100 years of aspirin safety history.
• Developed working formulations for several new sublingual products including melatonin (3mg, 5mg, 10mg doses), vitamins D, E, K, and testosterone.
• Launched caffeine products (Buzz Bomb Caffeine Co. LC) online in August 2025 after successful consumer and safety testing, and secured an additional manufacturing agreement for 2,000,000 units.
• Management believes the novel sublingual delivery mechanism for aspirin will be beneficial for patients needing rapid delivery and gastric bypass, potentially improving patient outcomes.
• Retained counsel with 30 years of FDA experience to assist in seeking approval for sublingual aspirin, with counsel believing the FDA would consider and welcome such a filing.

Negatives

• Reported a net loss of $17,922,621 for the six months ended June 30, 2025, significantly higher than $327,893 for the same period in 2024.
• Accumulated deficit reached $20,699,854 as of June 30, 2025.
• Working capital deficit was $9,567,500 as of June 30, 2025, with cash at only $206,233.
• Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern for the next twelve months.
• Received Nasdaq notices on April 16, 2025, for non-compliance with minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00) requirements, facing potential delisting.
• Identified material weaknesses in internal control over financial reporting, which could lead to additional material misstatements if not remediated.
• Previously acquired intellectual property (Instaprin patent applications and trademark) had expired or was cancelled due to failure to file maintenance documents, though new applications have been filed.
• Incurred a $364,109 loss on extinguishment of debt for the three and six months ended June 30, 2025, related to the amendment of the Blackstone Note.
• Significant stock-based compensation expense of $14,131,250 recognized in February 2025, contributing to the large net loss.

Risks

• History of operating losses and no assurance of future profitability or ability to raise additional financing.
• Need for substantial additional financing to achieve goals; failure to obtain capital could delay, limit, reduce, or terminate product development or commercialization efforts.
• Difficulties in managing growth as the organization increases in size.
• Dependence on experienced and skilled personnel; inability to attract and integrate such personnel could harm financial performance.
• Failure to adequately protect intellectual property rights could lead to revenue loss and harm operations and growth prospects.
• Market price of common stock may be volatile and fluctuate substantially, causing investment value to decline.
• Changes in accounting principles or their interpretation/implementation may adversely affect reported results.
• Failure to meet Nasdaq continued listing standards could result in delisting, affecting liquidity and market price.
• Material weaknesses in internal control over financial reporting, if not remediated, could lead to misstatements and adverse effects.
• Technology platforms and product candidates are based on novel technologies with unproven regulatory approval pathways, and products may not gain market acceptance.
• Business is highly dependent on the success of high-dose sublingual aspirin, requiring significant additional clinical testing and regulatory approval.
• Clinical development is lengthy, expensive, and uncertain; earlier trial results may not predict future outcomes, and trials may fail to demonstrate adequate safety and efficacy.
• Product candidates may cause undesirable side effects, halting development, preventing approval, or limiting commercial potential.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Reliance on third parties to conduct clinical trials; failure to carry out duties or meet deadlines could delay or prevent regulatory approval and commercialization.
• Failure to develop additional product candidates would limit commercial opportunity.
• Subject to manufacturing and supply chain risks, potentially increasing costs and limiting supply.
• Currently lacks in-house marketing and sales organization; inability to establish capabilities or secure third-party agreements could hinder revenue generation.
• Risks associated with marketing product candidates internationally could materially adversely affect the business.
• Significant competition from other biotechnology and pharmaceutical companies could negatively impact operating results.
• Employees, contractors, and partners may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Reliance on third parties to manufacture clinical product supplies and, if approved, commercial products; failure to obtain regulatory approval or provide sufficient quantities could stop or delay commercialization.
• Potential liability for damages if third-party manufacturers use hazardous and biological materials improperly.
• Price of common stock and warrants may fluctuate significantly post-business combination, leading to investment loss.
• Percentage ownership may be diluted by future issuances of capital stock.
• Resales of common stock by selling shareholders may cause the market price to fall.
• Investors buying shares at different times may pay different prices and experience different levels of dilution.
• This offering may cause the trading price of common stock to decrease.

Future Outlook

Aspire Biopharma intends to submit a section 505(b)(2) NDA for its high-dose sublingual aspirin product in Q3 2025, seeking fast-track approval. The company plans to build a focused sales and marketing organization in the United States for commercialization and explore third-party distribution internationally. Future product development includes conducting pharmacokinetic studies for melatonin, developing manufacturing processes and clinical trials for testosterone (Phase One in Q3 2026, NDA submission earliest Q4 2026), and finalizing a sublingual semaglutide formulation. The company anticipates taking several other drug and supplement formulations to market as R&D and funding dictate. Aspire will require additional financing to achieve its goals and fund future operations.

Management Comments

• Management believes that both results (faster bloodstream entry and more significant TXB2 impact for sublingual aspirin) are very positive.
• Management believes that the novel use of aspirin and its claims will be beneficial for some patients who need aspirin products that speed delivery and avoid the gastric tract.
• Counsel believes that the FDA would consider and even welcome a filing that is sufficient to support this novel mode of administration of certain aspirin products and would consider fast-track approval under 505(b)(2).
• Management believes that the consolidated financial statements included in the Form 10-K were prepared in accordance with US generally accepted accounting principles, despite identified material weaknesses in internal control over financial reporting.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Aspire Biopharma operates in this environment, aiming to disrupt with novel sublingual delivery mechanisms. The company notes that, to its knowledge, there are currently no sublingual aspirin products on the market, suggesting a potential first-mover advantage if regulatory approval is secured. However, it faces competition from major pharmaceutical companies like Bayer, Advil, and Tylenol in the broader aspirin market, which possess significantly greater financial, technical, and human resources. The industry also sees frequent mergers and acquisitions, concentrating resources among fewer competitors, and intense competition for skilled personnel and clinical study sites.

Comparison to Industry Standards

• Aspire's sublingual aspirin product demonstrated faster bloodstream entry and a more significant impact on TxB2 than conventional oral aspirin, suggesting a potential competitive advantage in speed of action.
• The company aims to compete with established oral aspirin products like Bayer aspirin, Advil, and Tylenol, but notes there are currently no sublingual aspirin products on the market, indicating a novel approach rather than direct competition against existing sublingual benchmarks.
• The company's financial performance, with significant net losses and a working capital deficit, falls below the typical financial health standards of established pharmaceutical companies, reflecting its early-stage biopharmaceutical status.

Management Changes

Corporate Governance

Legal Proceedings

• The former CEO of Instaprin Pharmaceuticals Inc., Donald A. Milne III, was convicted on a conspiracy to commit securities fraud charge, having diverted investor funds for personal use. A U.S. District Court issued a judgment against him and Instaprin Pharmaceuticals, Inc. for $4,182,627. Aspire acquired Instaprin's assets as part of a settlement sanctioned by this court.

Related Party Transactions

• Working Capital Loans: New Sponsor or affiliates loaned funds for transaction costs, repayable from Trust Account proceeds or outside funds. As of June 30, 2025, $499,214 was outstanding under loan and transfer agreements.
• Subscription Agreements: PowerUp entered into First and Second Subscription Agreements in March and May 2024, respectively, with the New Sponsor, an affiliate, and investors, totaling $1,500,000 in debt assumed by the company as of February 17, 2025.
• Due to Affiliate: As of June 30, 2025, $353,679 was accrued and outstanding to the sponsor of PowerUp for administrative services fees and a residual balance from IPO proceeds.
• Promissory Note Fee: On October 2, 2024, PowerUp agreed to pay the Sponsor a modified promissory note fee of $1,000,000 upon successful closing of a business combination, which remains outstanding as of June 30, 2025.
• Notes Payable Related Party: Aspire Biopharma, Inc. incurred expenses and costs related to officer and director compensation, office space rental, and reimbursable expenses paid by affiliates. In 2024, these advances were formalized into non-convertible 20% OID notes payable to related parties, totaling $1,331,357 outstanding as of June 30, 2025.
• Securities Purchase Agreement: On February 17, 2025, the company entered into an agreement with Cobra Alternative Capital Strategies, LLC (controlled by former Director of Investor Relations Lance Friedman) and Target Capital X LLC, issuing 20% OID senior secured convertible debentures for an aggregate principal of $3,750,000. Commitment fee shares (2,106,527) were transferred by affiliates to these investors.
• Blackstone Subscription Agreement: On December 18, 2024, the company entered into an agreement with Blackstone Capital Advisors, Inc. (controlled by Lance Friedman), which loaned up to $500,000. This agreement was amended on February 17, 2025, to fix commitment shares to 1,795,000, and further amended on April 24, 2025, to extend the maturity date to August 15, 2025, and included a $60,000 addition to principal for a waiver of default rights.

Stakeholder Impact

• Shareholders face significant dilution risk from the registration of up to 147,177,424 shares for resale and potential future equity raises.
• Existing shareholders may experience a decrease in share price due to the large volume of shares being registered for resale and the company's current low market price and Nasdaq compliance issues.
• Investors are exposed to substantial risk due to the company's history of operating losses, significant accumulated deficit, and management's expressed doubt about its ability to continue as a going concern.
• Employees and management may face uncertainty given the company's financial instability and the ongoing search for a permanent CEO.
• Creditors and lenders are impacted by the company's high debt levels, including convertible notes and related party loans, and the potential for default, although some debt has been repaid from recent financing.
• Customers (future) could benefit from novel sublingual drug delivery products, particularly for aspirin, if regulatory approvals are secured and commercialization is successful, offering faster and potentially safer alternatives.

Next Steps

• Submit a section 505(b)(2) NDA for high-dose sublingual aspirin in Q3 2025 and seek fast-track approval.
• Potentially conduct a later clinical trial in approximately 24 healthy human volunteers to evaluate the pharmacodynamic effect of high-dose aspirin on platelet inhibition.
• Conduct additional clinical trials to differentiate aspirin based on TXB2 inhibition and gastrointestinal irritation for other therapeutic indications.
• Conduct a limited pharmacokinetic study for sublingually administered melatonin.
• File patent applications for melatonin, vitamins D, E, K, and testosterone formulations.
• Develop and validate the manufacturing process for sublingual testosterone in Q1/Q2 2026, subject to funding.
• Conduct a Phase One clinical test for sublingual testosterone in approximately Q3 2026.
• Request a pre-IND meeting with the FDA for testosterone in Q4 2026, followed by Phase Two clinical testing.
• Submit an NDA for the testosterone product under 505(b)(2) to the FDA in Q4 2026 at the earliest.
• Continue final phases of developing a working formulation for a sublingual semaglutide product.
• Consider formulations for anti-nausea, anti-psychotic, ED drugs, seizure medication, and other drug classes.
• Hold a special meeting of stockholders on November 4, 2025, to approve the issuance of more than 19.99% of outstanding shares upon conversion of Notes and the floor price, and to grant discretionary authority for a reverse stock split.
• Actively search for a permanent Chief Executive Officer.
• Implement measures to regain compliance with Nasdaq listing standards (MVLS and bid price) by October 13, 2025.

Key Dates

Recommendation

Aspire Biopharma is in a precarious financial position, evidenced by substantial and increasing net losses, a significant accumulated deficit, and a critical working capital deficit. Management explicitly states there is 'substantial doubt about the Company’s ability to continue as a going concern.' Furthermore, the company faces immediate threats of delisting from Nasdaq due to non-compliance with both minimum market value and bid price requirements. While the positive clinical trial results for sublingual aspirin offer long-term potential, the severe liquidity issues, high dilution risk from current and future capital raises, and the overall financial instability make the stock a high-risk investment with a strong likelihood of further value erosion. The operational positives are heavily outweighed by the existential financial threats.

Keywords

Biopharma, Sublingual Delivery, Aspirin, Pharmaceuticals, SEC Filing, S-1/A, Clinical Trials, FDA Approval, Drug Development, Convertible Notes, Nasdaq Delisting, Going Concern, Intellectual Property, Caffeine Supplements, Melatonin, Testosterone, Semaglutide, Biotechnology, Financial Reporting, Risk Factors